[6-K] Inspira Technologies Oxy B.H.N. Ltd. Warrant Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Inspira Technologies Oxy B.H.N. Ltd. disclosed a press release dated September 2, 2025 announcing that a top U.S. Honor Roll hospital has expanded clinical use of the company’s INSPIRA™ ART100 system to include lung transplant procedures. The filing reproduces the press release and is signed by Dagi Ben-Noon, Chief Executive Officer. The statement highlights broader clinical adoption of the ART100 device but does not provide revenue, patient counts, contract terms, or trial results in this filing.

Positive

• Clinical adoption of the INSPIRA ART100 expanded to lung transplant procedures
• Adoption reported by a Top U.S. Honor Roll hospital, supporting credibility

Negative

• None.

Insights

Medical Devices Analyst

Expansion signals wider clinical adoption but lacks commercial detail.

The press release shows the INSPIRA ART100 is now used in lung transplant procedures at a top-ranked U.S. hospital, which may support clinical credibility and adoption momentum.

However, the filing contains no information on contract value, patient volumes, or reimbursement status, so the immediate financial impact is unclear.

Regulatory / Clinical Affairs Specialist

Clinical expansion is notable but provides no regulatory or outcome data.

The notice documents an institutional expansion of use but does not detail trial results, endpoints, or regulatory clearances tied to lung transplant use.

Without outcome metrics or formal study references, this item is primarily a clinical-adoption update rather than a demonstrated efficacy or regulatory milestone.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September 2025

Commission File Number: 001-40303

Inspira Technologies Oxy B.H.N. Ltd.

(Translation of registrant’s name into English)

2 Ha-Tidhar St.

Ra’anana 4366504, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F        ☐ Form 40-F

CONTENTS

On September 2, 2025, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “Top U.S. Honor Roll Hospital Expands Use of Inspira ART100 System to Lung Transplant Procedures,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

The first, second, and fourth paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (Registration Nos. 333-266748, 333-284308, and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980 and 333-285565), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.
99.1		Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on September 2, 2025, titled “Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures.”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Inspira Technologies Oxy B.H.N. Ltd.
Date: September 2, 2025	By:	/s/ Dagi Ben-Noon
		Name:	Dagi Ben-Noon
		Title:	Chief Executive Officer

2

FAQ

What did Inspira (IINNW) announce in the September 2, 2025 filing?

The company disclosed a press release stating a top U.S. Honor Roll hospital has expanded use of the INSPIRA ART100 system to lung transplant procedures.

Does the filing include financial details about the hospital agreement?

No. The filing does not provide contract values, revenue figures, or commercial terms.

Who signed the 6-K filing for Inspira?

The filing is signed by Dagi Ben-Noon, Chief Executive Officer.

Does the press release provide patient outcomes or clinical trial data?

No. The release notes expanded clinical use but does not include patient outcome data or trial results.

Is the expansion described here a regulatory approval?

The filing does not state any new regulatory approval; it reports expanded clinical use at a hospital.